Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Breelyn Wilky

Concepts (267)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
21
2025
205
7.300
 Why?
Soft Tissue Neoplasms
9
2024
127
2.870
 Why?
Gastrointestinal Stromal Tumors
6
2026
40
2.060
 Why?
Molecular Targeted Therapy
8
2026
432
1.590
 Why?
Antineoplastic Combined Chemotherapy Protocols
7
2025
1953
1.570
 Why?
Immunotherapy
10
2023
653
1.550
 Why?
Bone Neoplasms
9
2025
253
1.490
 Why?
Sarcoma, Alveolar Soft Part
2
2023
6
1.380
 Why?
Hemangiosarcoma
2
2021
23
1.210
 Why?
CTLA-4 Antigen
2
2025
104
1.090
 Why?
Precision Medicine
3
2024
457
1.000
 Why?
Neoplasm Recurrence, Local
4
2025
1137
0.910
 Why?
Biomarkers, Tumor
8
2022
1313
0.910
 Why?
Antineoplastic Agents
8
2023
2194
0.910
 Why?
Circulating Tumor DNA
2
2022
43
0.740
 Why?
Antibodies, Monoclonal, Humanized
6
2025
985
0.740
 Why?
Leiomyosarcoma
1
2022
28
0.730
 Why?
Pyrimidines
2
2018
532
0.710
 Why?
Sulfonamides
2
2018
580
0.700
 Why?
Chondrosarcoma
4
2025
17
0.660
 Why?
Sarcoma, Ewing
2
2025
102
0.620
 Why?
Immunomodulation
2
2019
101
0.590
 Why?
Antineoplastic Agents, Immunological
3
2019
199
0.560
 Why?
Combined Modality Therapy
7
2026
1266
0.550
 Why?
Humans
64
2026
144759
0.550
 Why?
Salvage Therapy
1
2019
162
0.550
 Why?
Neoplasms
5
2024
2875
0.480
 Why?
Medical Oncology
3
2025
332
0.460
 Why?
Neovascularization, Pathologic
1
2017
286
0.440
 Why?
DEAD-box RNA Helicases
1
2015
90
0.430
 Why?
Programmed Cell Death 1 Receptor
3
2025
264
0.430
 Why?
Diffusion Magnetic Resonance Imaging
1
2015
154
0.410
 Why?
Prognosis
8
2025
4282
0.410
 Why?
Solitary Fibrous Tumors
1
2013
3
0.410
 Why?
Thoracic Neoplasms
1
2013
39
0.390
 Why?
Giant Cell Tumor of Tendon Sheath
2
2024
8
0.390
 Why?
Liposarcoma
2
2023
31
0.380
 Why?
Sarcoma, Synovial
2
2024
20
0.360
 Why?
Giant Cell Tumor of Bone
2
2021
8
0.340
 Why?
Adult
22
2026
40449
0.330
 Why?
Treatment Outcome
11
2026
11679
0.330
 Why?
Antigens, Neoplasm
2
2024
271
0.320
 Why?
Bone Density Conservation Agents
2
2021
81
0.320
 Why?
Magnetic Resonance Imaging
3
2021
3863
0.310
 Why?
Brain Neoplasms
1
2019
1318
0.300
 Why?
Disease Management
2
2026
645
0.290
 Why?
Middle Aged
17
2026
35875
0.280
 Why?
Melanoma
2
2025
761
0.280
 Why?
Isocitrate Dehydrogenase
3
2025
70
0.270
 Why?
Doxorubicin
2
2025
397
0.270
 Why?
Receptor, Platelet-Derived Growth Factor alpha
2
2019
54
0.270
 Why?
T-Lymphocytes
4
2026
1982
0.270
 Why?
Aged
14
2026
25913
0.270
 Why?
Protein Kinase Inhibitors
4
2024
969
0.260
 Why?
Male
20
2026
72315
0.260
 Why?
Imidazoles
3
2023
254
0.250
 Why?
Ovarian Neoplasms
2
2025
586
0.250
 Why?
Female
21
2026
78271
0.240
 Why?
Succinate Dehydrogenase
1
2026
57
0.240
 Why?
Receptors, Fibroblast Growth Factor
1
2026
69
0.240
 Why?
Mutation
6
2025
4089
0.230
 Why?
Neoplasm Metastasis
4
2025
688
0.230
 Why?
Gastrointestinal Neoplasms
1
2026
70
0.230
 Why?
Protein Tyrosine Phosphatase, Non-Receptor Type 22
1
2025
48
0.230
 Why?
Interleukin-1 Receptor-Associated Kinases
1
2025
40
0.230
 Why?
Indazoles
2
2018
80
0.230
 Why?
Liquid Biopsy
2
2022
13
0.220
 Why?
DNA-Activated Protein Kinase
1
2024
15
0.220
 Why?
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
1
2024
16
0.220
 Why?
Receptors, Antigen, T-Cell
2
2026
668
0.210
 Why?
Hemangioendothelioma, Epithelioid
1
2024
7
0.210
 Why?
Osteosarcoma
1
2025
76
0.210
 Why?
Denosumab
2
2021
10
0.210
 Why?
Liposarcoma, Myxoid
1
2024
10
0.210
 Why?
Sodium Tetradecyl Sulfate
1
2024
2
0.210
 Why?
Oncologists
1
2025
46
0.210
 Why?
Cell Line, Tumor
7
2026
3540
0.210
 Why?
Electroporation
1
2024
41
0.210
 Why?
Imatinib Mesylate
1
2024
77
0.200
 Why?
Tumor Microenvironment
4
2025
732
0.200
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2023
31
0.200
 Why?
Cancer Vaccines
3
2019
160
0.190
 Why?
Tetrahydronaphthalenes
1
2023
31
0.190
 Why?
Job Satisfaction
1
2025
240
0.180
 Why?
Young Adult
9
2025
14105
0.180
 Why?
Anemia
1
2024
188
0.180
 Why?
Neoplasms, Second Primary
1
2023
100
0.180
 Why?
Thrombocytopenia
1
2024
205
0.180
 Why?
Cytotoxicity, Immunologic
2
2019
223
0.180
 Why?
Academic Medical Centers
1
2025
547
0.170
 Why?
Survival Rate
2
2019
2089
0.170
 Why?
Response Evaluation Criteria in Solid Tumors
1
2021
21
0.170
 Why?
Translocation, Genetic
2
2019
115
0.170
 Why?
Quinazolines
1
2023
266
0.170
 Why?
Clinical Trials, Phase II as Topic
3
2019
77
0.170
 Why?
Animals
12
2026
38058
0.170
 Why?
Postoperative Complications
1
2013
2919
0.160
 Why?
Immunotherapy, Adoptive
2
2026
337
0.160
 Why?
beta Catenin
1
2022
252
0.160
 Why?
Chromosomes, Human, Pair 12
1
2019
21
0.160
 Why?
Chromosomes, Human, Pair 7
1
2019
17
0.160
 Why?
Osteoblasts
1
2021
145
0.160
 Why?
Zinc Finger Protein GLI1
1
2019
26
0.150
 Why?
Gene Fusion
1
2019
29
0.150
 Why?
Oncogene Fusion
1
2019
11
0.150
 Why?
Chemoradiotherapy
1
2021
237
0.150
 Why?
Immunity, Innate
1
2025
846
0.150
 Why?
Neoplasm Staging
4
2018
1462
0.150
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2019
85
0.150
 Why?
Retrospective Studies
6
2024
17066
0.150
 Why?
Gene Amplification
1
2019
120
0.150
 Why?
Tumor Escape
1
2019
49
0.150
 Why?
Indoles
1
2023
501
0.140
 Why?
High-Throughput Nucleotide Sequencing
1
2022
549
0.140
 Why?
Transcriptome
1
2025
1045
0.140
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.140
 Why?
Neurofibrosarcoma
1
2018
7
0.140
 Why?
Carcinogenesis
1
2019
229
0.130
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
230
0.130
 Why?
Liver Neoplasms
1
2024
780
0.130
 Why?
Hematology
1
2017
21
0.130
 Why?
Drug Resistance, Neoplasm
2
2025
881
0.130
 Why?
Aged, 80 and over
6
2025
8265
0.130
 Why?
Actins
1
2019
425
0.130
 Why?
Radiography
2
2021
844
0.130
 Why?
Gene Expression Regulation, Neoplastic
3
2025
1455
0.130
 Why?
Drug Administration Schedule
1
2019
779
0.130
 Why?
T-Lymphocyte Subsets
1
2019
415
0.130
 Why?
Follow-Up Studies
2
2019
5408
0.130
 Why?
Rhabdoid Tumor
1
2018
103
0.120
 Why?
Quality of Life
2
2026
3185
0.120
 Why?
Colorectal Neoplasms
1
2024
845
0.120
 Why?
Clinical Trials as Topic
1
2021
1053
0.120
 Why?
Glutarates
1
2015
11
0.120
 Why?
Benzeneacetamides
1
2015
8
0.120
 Why?
Drug Discovery
1
2017
155
0.120
 Why?
Lymphocytes, Tumor-Infiltrating
3
2024
154
0.110
 Why?
Mice
7
2026
18339
0.110
 Why?
Simulation Training
1
2017
134
0.110
 Why?
Azepines
1
2015
107
0.110
 Why?
Receptor, IGF Type 1
1
2014
64
0.110
 Why?
Gene Knockdown Techniques
1
2015
336
0.110
 Why?
Apoptosis
3
2023
2430
0.100
 Why?
MAP Kinase Kinase Kinases
1
2014
70
0.100
 Why?
Paired Box Transcription Factors
1
2014
43
0.100
 Why?
Tomography, X-Ray Computed
1
2024
2730
0.100
 Why?
Chordoma
1
2013
17
0.100
 Why?
Macrophages
1
2021
1511
0.100
 Why?
TOR Serine-Threonine Kinases
1
2017
449
0.100
 Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2016
338
0.100
 Why?
Fellowships and Scholarships
1
2017
357
0.100
 Why?
Benzimidazoles
1
2014
190
0.100
 Why?
Clinical Trials, Phase III as Topic
1
2013
117
0.100
 Why?
Rhabdomyosarcoma
1
2014
64
0.100
 Why?
Drug Screening Assays, Antitumor
1
2013
191
0.100
 Why?
Membrane Proteins
1
2019
1166
0.100
 Why?
Forkhead Transcription Factors
1
2014
202
0.090
 Why?
Genetic Predisposition to Disease
2
2019
2363
0.090
 Why?
Drug Monitoring
1
2016
395
0.090
 Why?
Disease-Free Survival
1
2014
769
0.090
 Why?
Antibodies, Monoclonal
2
2023
1519
0.090
 Why?
Xenograft Model Antitumor Assays
1
2015
928
0.090
 Why?
HLA-A Antigens
2
2024
52
0.090
 Why?
Connective Tissue
2
2022
39
0.090
 Why?
Enzyme Inhibitors
1
2015
824
0.090
 Why?
Oncogene Proteins, Fusion
1
2014
210
0.090
 Why?
Angiogenesis Inhibitors
1
2013
237
0.090
 Why?
Sirolimus
1
2013
281
0.080
 Why?
Curriculum
1
2017
1059
0.080
 Why?
Immunohistochemistry
3
2021
1716
0.080
 Why?
NF-kappa B
1
2013
661
0.080
 Why?
Clinical Trials, Phase I as Topic
2
2019
52
0.070
 Why?
Signal Transduction
3
2026
5226
0.070
 Why?
Neoplasm Grading
2
2018
307
0.060
 Why?
Randomized Controlled Trials as Topic
1
2013
1720
0.060
 Why?
CD3 Complex
1
2026
111
0.060
 Why?
Myeloid Differentiation Factor 88
1
2026
114
0.060
 Why?
Receptor, Macrophage Colony-Stimulating Factor
1
2024
11
0.050
 Why?
Chromones
1
2024
42
0.050
 Why?
Career Mobility
1
2025
71
0.050
 Why?
Ifosfamide
1
2024
38
0.050
 Why?
DNA Copy Number Variations
1
2025
183
0.050
 Why?
Microsatellite Instability
1
2024
54
0.050
 Why?
Anilides
1
2024
84
0.050
 Why?
Adolescent
4
2021
22428
0.050
 Why?
Morpholines
1
2024
128
0.050
 Why?
Cohort Studies
1
2014
5960
0.050
 Why?
Frameshift Mutation
1
2023
32
0.050
 Why?
Activating Transcription Factor 4
1
2023
22
0.050
 Why?
Proteasome Inhibitors
1
2023
40
0.050
 Why?
Microsatellite Repeats
1
2024
157
0.050
 Why?
Gene Expression Profiling
2
2025
1782
0.050
 Why?
Quinolines
1
2024
193
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
66
0.050
 Why?
Workload
1
2025
170
0.050
 Why?
Valine
1
2023
80
0.050
 Why?
Disease Progression
2
2022
2847
0.050
 Why?
Amyloid Precursor Protein Secretases
1
2023
77
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
159
0.050
 Why?
Cell Differentiation
2
2021
2050
0.050
 Why?
Observational Studies as Topic
1
2022
129
0.040
 Why?
Chemical and Drug Induced Liver Injury
1
2023
139
0.040
 Why?
Killer Cells, Natural
1
2025
467
0.040
 Why?
Gastrointestinal Hemorrhage
1
2022
136
0.040
 Why?
Neoplasm Proteins
1
2024
442
0.040
 Why?
Cell Movement
1
2025
965
0.040
 Why?
DNA Methylation
1
2026
681
0.040
 Why?
Piperazines
1
2023
381
0.040
 Why?
Cytokines
2
2019
2061
0.040
 Why?
T-Cell Antigen Receptor Specificity
1
2019
45
0.040
 Why?
Mice, Nude
1
2021
682
0.040
 Why?
Genomics
1
2025
834
0.040
 Why?
Reactive Oxygen Species
1
2022
621
0.040
 Why?
Tumor Suppressor Protein p53
1
2023
529
0.040
 Why?
Prospective Studies
2
2022
7990
0.040
 Why?
Cross-Over Studies
1
2021
601
0.040
 Why?
Cell Lineage
1
2021
376
0.040
 Why?
Oncolytic Viruses
1
2018
8
0.030
 Why?
Oncolytic Virotherapy
1
2018
13
0.030
 Why?
Organ Sparing Treatments
1
2018
38
0.030
 Why?
Margins of Excision
1
2018
51
0.030
 Why?
Double-Blind Method
1
2023
2029
0.030
 Why?
SMARCB1 Protein
1
2018
34
0.030
 Why?
Radiotherapy, Adjuvant
1
2018
222
0.030
 Why?
SEER Program
1
2018
224
0.030
 Why?
Mice, Knockout
1
2024
3121
0.030
 Why?
DNA-Binding Proteins
1
2024
1499
0.030
 Why?
Syndrome
1
2018
380
0.030
 Why?
Germ-Line Mutation
1
2018
172
0.030
 Why?
Pedigree
1
2018
514
0.030
 Why?
Cell- and Tissue-Based Therapy
1
2017
80
0.030
 Why?
Models, Molecular
1
2021
1618
0.030
 Why?
Rats, Sprague-Dawley
1
2021
2527
0.030
 Why?
Immune System
1
2017
179
0.030
 Why?
Risk
1
2018
911
0.030
 Why?
Surgical Procedures, Operative
1
2018
270
0.030
 Why?
Population Surveillance
1
2018
485
0.030
 Why?
Incidence
1
2021
2879
0.030
 Why?
PAX3 Transcription Factor
1
2014
17
0.030
 Why?
Radiation
1
2014
24
0.030
 Why?
Cell Proliferation
1
2021
2496
0.030
 Why?
Forkhead Box Protein O1
1
2014
36
0.030
 Why?
Mutation, Missense
1
2015
340
0.020
 Why?
Cell Cycle Checkpoints
1
2014
99
0.020
 Why?
Transplantation, Heterologous
1
2013
193
0.020
 Why?
Chondrocytes
1
2015
232
0.020
 Why?
Program Evaluation
1
2017
948
0.020
 Why?
Rats
1
2021
5597
0.020
 Why?
Education, Medical, Graduate
1
2017
557
0.020
 Why?
Sensitivity and Specificity
1
2016
1985
0.020
 Why?
Phenotype
1
2019
3162
0.020
 Why?
Communication
1
2017
965
0.020
 Why?
Disease Models, Animal
1
2021
4557
0.020
 Why?
Polymerase Chain Reaction
1
2013
1054
0.020
 Why?
Adaptation, Physiological
1
2014
570
0.020
 Why?
Recurrence
1
2013
1135
0.020
 Why?
Genotype
1
2013
1833
0.020
 Why?
Dose-Response Relationship, Drug
1
2013
2027
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2017
1414
0.020
 Why?
Reproducibility of Results
1
2016
3409
0.020
 Why?
Biomarkers
1
2019
4271
0.020
 Why?
United States
1
2025
15966
0.020
 Why?
Child
2
2019
22633
0.020
 Why?
Polymorphism, Single Nucleotide
1
2013
2145
0.010
 Why?
Surveys and Questionnaires
1
2017
6048
0.010
 Why?
Child, Preschool
1
2019
11787
0.010
 Why?
Infant
1
2018
10034
0.010
 Why?
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (267) concept(s)
_
Co-Authors Expand Description
See all (29) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)